Patients who had suffered an episode of acute myocardial infarction appear to show heightened levels of hair cortisol, indicative of biological stress, in the preceding month, a recent study has found.
A single polypill combining a beta blocker, ACE* inhibitor, statin, and diuretic, in addition to a daily dose of aspirin, significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate CV risk, according to the TIPS**-3 study presented at the AHA 2020 Scientific Sessions.
In older women with early breast cancer, using statins after completing a chemotherapy containing anthracyclines appears to reduce the risk of hospitalizations for heart failure, as reported in a study.
Usinga fully-automated deep learning analysis of an abdominal computed tomography (CT) image to measure visceral fat area may predict future major cardiovascular (CV) outcomes, particularly heart attack and stroke, according to a study presented at RSNA 2020.
Add-on eptifibatide, infused intravenously, seems to be unnecessary for the adjunctive antithrombotic treatment during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction (STEMI), a recent study has found.
Eating more than one egg a day does not result in any cardiovascular disease (CVD) but even appears to be preventive of coronary artery disease (CAD), suggest the results of a systematic review and meta-analysis.
Among diabetic individuals, the incidence of hospitalization for heart failure (HHF) is low but not negligible, a new study finds. In addition, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) could help suppress HHF.
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.